Burn-induced muscle mass loss and decrease in tension generating capacity, due to the nitrogen catabolic state, increase morbidity and mortality. The goals of this proposal are to identify novel potential molecular targets and apply untested pharmacological approaches to prevent the catabolic state and muscle wasting in burns in mice. In view of the heterogeneous effects of burn on diverse signaling pathways, an integrated multi-pronged approach to modulate the manifold effects of burn on muscle metabolism is proposed. This approach will be achieved by the Specific Aims, which test three hypotheses:
Specific Aim 1 : (a) that burn injury-induced activation of GSK-3beta leads to muscle wasting mainly by suppressing beta-catenin pathway;(b) that GSK-3|3 inhibitor (SB216763) will correct these aberrations and ameliorate muscle wasting of burns.
Specific Aim 2 : that SIRTI deacetylase function is depressed in muscle following burns, as reflected by increased acetylation of p53, NF-KBeta and PGC-1 a, contributing to mitochondria-mediated apoptotic changes and enhanced inflammatory response, and subsequent muscle wasting, all of which will be mitigated by SIRTI activator (SRT1720).
Specific Aim 3 : that burn injury induces increased protein farnesylation leading to activation of the Ras (a major target of farnesylation)-JNK pathway, and decreased anabolic signaling via the IRS-1-Akt pathway;(b) that inhibition of farnesylation by statin or FTI-277 will reverse these alterations and thereby prevent muscle mass loss in burns. The proposed studies combine in vivo muscle physiology, molecular pharmacology and genetic approaches (using muscle-specific knockout mice for GSK-3BETA, SIRTI and farnesyltransferase), together with genome-wide gene expression and transcriptome analyses. This will advance our knowledge of organismal pathophysiology and function at multiple levels from genes to proteins, from cellular responses to organ (whole muscle) function, and of cross talks between signaling pathways mediated by GSK-3beta, SIRTI and farnesylation in muscle metabolic dysregulation in burns. This project is designed to determine whether inhibitors/activator for GSK-3BETA, SIRTI, and farnesyltransferase are novel potential strategies to reverse muscle wasting and metabolic derangements in burn patients.
The results of the proposed studies will not only provide novel mechanistic insights in muscle wasting of burns, but also use untested strategies to rectify the muscle wasting after burn injury. The results from these studies, when applied to patients, will help improve the clinical complications associated with loss of muscle mass and muscle function.
|Zhao, Gaofeng; Yu, Yong-Ming; Kaneki, Masao et al. (2015) Simvastatin reduces burn injury-induced splenic apoptosis via downregulation of the TNF-?/NF-?B pathway. Ann Surg 261:1006-12|
|Watada, Susumu; Yu, Yong-Ming; Fischman, Alan J et al. (2014) Evaluation of intragastric vs intraperitoneal glucose tolerance tests in the evaluation of insulin resistance in a rodent model of burn injury and glucagon-like polypeptide-1 treatment. J Burn Care Res 35:e66-72|
|Zhao, Gaofeng; Yu, Yong-Ming; Shoup, Timothy M et al. (2014) Membrane potential-dependent uptake of 18F-triphenylphosphonium--a new voltage sensor as an imaging agent for detecting burn-induced apoptosis. J Surg Res 188:473-9|
|Carter, Edward A; Paul, Kasie; Bonab, Ali A et al. (2014) Effect of exercise on burn-induced changes in tissue-specific glucose metabolism. J Burn Care Res 35:470-3|
|Lee, Sangseok; Yang, Hong-Seuk; Sasakawa, Tomoki et al. (2014) Immobilization with atrophy induces de novo expression of neuronal nicotinic *7 acetylcholine receptors in muscle contributing to neurotransmission. Anesthesiology 120:76-85|
|Fu, Glenn K; Xu, Weihong; Wilhelmy, Julie et al. (2014) Molecular indexing enables quantitative targeted RNA sequencing and reveals poor efficiencies in standard library preparations. Proc Natl Acad Sci U S A 111:1891-6|
|Khan, Mohammed A S; Sahani, Nita; Neville, Kevin A et al. (2014) Nonsurgically induced disuse muscle atrophy and neuromuscular dysfunction upregulates alpha7 acetylcholine receptors. Can J Physiol Pharmacol 92:1-8|
|Ueda, Masashi; Iwasaki, Hajime; Wang, Shuxing et al. (2014) Cannabinoid receptor type 1 antagonist, AM251, attenuates mechanical allodynia and thermal hyperalgesia after burn injury. Anesthesiology 121:1311-9|
|Ibrahim, Amir; Fagan, Shawn; Keaney, Tim et al. (2014) A simple cost-saving measure: 2.5% mafenide acetate solution. J Burn Care Res 35:349-53|
|Shank, Erik S; Martyn, Jeevendra A; Donelan, Mathias B et al. (2014) Ultrasound-Guided Regional Anesthesia for Pediatric Burn Reconstructive Surgery: A Prospective Study. J Burn Care Res :|
Showing the most recent 10 out of 77 publications